The tariff classification of RVU305 in bulk form, from China
No revocation or modification of this ruling appears in the Customs Bulletin issues read here (Nov 6, 2024 through Nov 18, 2026), where CBP publishes most such actions. That is not confirmation that the ruling is still in effect. Confirm its status with CBP before relying on it (ruling on CBP CROSS).
Key passages, quoted from the ruling
- The applicable subheading for the subject merchandise will be 9817.85.01, HTSUS, which provides for “Prototypes to be used exclusively for development, testing, product evaluation, or quality control purposes.” The rate of duty will be free.
Ruling text
In your letter dated July 23, 2025, you requested a tariff classification ruling. RVU305 is an MTA-cooperative PRMT5 inhibitor that selectively impedes the growth of cancer cells with MTAP deletions, while sparing normal cells. The RVU305 will be undergoing drug development in the pre-IND stage for use in Phase 1 clinical studies. In your letter, you indicated the RVU305 will be imported in bulk form and formulated into dosage form tablets for first-in-human, Phase I clinical studies on solid tumors.
The applicable subheading for the RVU305 in bulk form will be 2934.99.3900, Harmonized Tariff Schedule of the United States (HTSUS), which provides for “Nucleic acids and their salts, whether or not chemically defined; other heterocyclic compounds: Other: Other: Aromatic or modified aromatic: Other: Other: Products described in additional U.S. note 3 to section VI.” The general rate of duty will be 6.5 percent ad valorem.
Effective March 4, 2025, pursuant to U.S. Note 2(u) to Subchapter III, Chapter 99, all products of China and Hong Kong as provided by heading 9903.01.24, HTSUS, other than products classifiable under headings 9903.01.21, 9903.01.22, and 9903.01.23, HTSUS, will be subject to an additional 20 percent ad valorem rate of duty. At the time of entry, you must report the applicable Chapter 99 heading, i.e. 9903.01.24, in addition to subheading 2934.99.3900, HTSUS, listed above.
Effective April 5, 2025, Executive Orders implemented “Reciprocal Tariffs.” All imported merchandise must be reported with either the Chapter 99 provision under which the reciprocal tariff applies or one of the Chapter 99 provisions covering exceptions to the reciprocal tariffs. At this time, products of China, Hong Kong, and Macau will be assessed an additional ad valorem rate of duty of 10 percent. Your product falls within an excepted subheading.
At the time of entry, you must report the Chapter 99 heading applicable to your product classification, i.e. 9903.01.32, in addition to subheading 2934.99.3900, HTSUS, listed above.
You also inquired about whether the imported RVU305 qualifies for duty free treatment as a prototype under subheading 9817.85.01, HTSUS, which provides for “Prototypes to be used exclusively for development, testing, product evaluation, or quality control purposes.” You indicated that the RVU305 will be imported solely for use in Phase 1 clinical studies. You also stated the RVU305 will be imported in approximately 10 kg in limited non-commercial quantities solely for use in clinical trials.
You further indicate the imported product will not be sold and it is not subject to any quantitative restrictions, antidumping orders, or countervailing duty orders. Based on the information presented, we find that RVU305, qualifies for duty free treatment as a prototype under subheading 9817.85.01, HTSUS, provided that all of the conditions delineated in U.S. Note 7, Chapter 98, Subchapter XVII, Harmonized Tariff Schedule of the United States, (HTSUS) are satisfied.
The text above is an excerpt. The official ruling, with its letterhead, signature and any attachments, is on CBP CROSS (N351608).